​

Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRL Stock Forecast

Charles River Laboratories stock forecast is as follows: an average price target of $209.00 (represents a 14.74% upside from CRL’s last price of $182.15) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

CRL Price Target

The average price target for Charles River Laboratories (CRL) is $209.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $240.00 to $151.00. This represents a potential 14.74% upside from CRL's last price of $182.15.

CRL Analyst Ratings

Buy

According to 11 Wall Street analysts, Charles River Laboratories's rating consensus is 'Buy'. The analyst rating breakdown for CRL stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 3 'Hold' (27.27%), 2 'Sell' (18.18%), and 0 'Strong Sell' (0.00%).

Charles River Laboratories Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 15, 2024Luke SergottBarclays$205.00$193.146.14%12.54%
Oct 14, 2024Jamie ClarkRedburn Partners$151.00$192.97-21.75%-17.10%
Sep 17, 2024Ann HynesMizuho Securities$210.00$206.441.73%15.29%
Aug 08, 2024Justin BowersDeutsche Bank$240.00$200.3419.80%31.76%
Jul 10, 2024Eric ColdwellRobert W. Baird$239.00$201.8518.40%31.21%
Jun 28, 2024Luke SergottBarclays$230.00$207.3510.92%26.27%
Jun 06, 2024Matthew SykesGoldman Sachs$290.00$216.1234.18%59.21%
May 09, 2024Elizabeth AndersonEvercore ISI$265.00$230.0915.17%45.48%
Apr 01, 2024Elizabeth AndersonEvercore ISI$300.00$270.9510.72%64.70%
May 05, 2022Donald HookerKeyBanc$300.00$257.5116.50%64.70%
Apr 25, 2022Wells Fargo$325.00$257.7526.09%78.42%
Apr 25, 2022David WindleyJefferies$280.00$273.032.55%53.72%
Jan 11, 2022David WindleyJefferies$464.00$357.9529.63%154.74%
Nov 24, 2021David ToungArgus Research$440.00$377.5116.55%141.56%
Aug 17, 2021Daniel BrennanCowen & Co.$465.00$417.4511.39%155.28%
Aug 04, 2021Katie TryhaneCredit Suisse$385.00$416.31-7.52%111.36%
May 28, 2021Tycho PetersonJ.P. Morgan$390.00$337.9915.39%114.11%
May 25, 2021Sandy DraperGuggenheim$369.00$329.5211.98%102.58%

The latest Charles River Laboratories stock forecast, released on Oct 15, 2024 by Luke Sergott from Barclays, set a price target of $205.00, which represents a 6.14% increase from the stock price at the time of the forecast ($193.14), and a 12.54% increase from CRL last price ($182.15).

Charles River Laboratories Price Target by Period

1M3M12M
# Anlaysts-29
Avg Price Target-$178.00$236.67
Last Closing Price$182.15$182.15$182.15
Upside/Downside-100.00%-2.28%29.93%

In the current month, the average price target of Charles River Laboratories stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Charles River Laboratories's last price of $182.15. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024CLSAUnderperformInitialise
Oct 15, 2024BarclaysEqual-WeightEqual-WeightHold
Oct 01, 2024CitigroupBuySellDowngrade
Aug 08, 2024Deutsche BankBuyBuyHold
Jun 27, 2024BarclaysEqual-WeightInitialise
Jun 06, 2024Goldman SachsBuyInitialise
May 13, 2024Cowen & Co.HoldHoldHold
May 09, 2024Evercore ISIOutperformOutperformHold
Apr 01, 2024Evercore ISIOutperformOutperformHold
Feb 23, 2023GuggenheimBuyUpgrade
Jan 12, 2023JefferiesBuyHoldDowngrade
Nov 09, 2022Bank of America SecuritiesBuyReduceDowngrade
Nov 03, 2022CFRABuyUpgrade
Sep 29, 2022JefferiesHoldBuyUpgrade
Aug 24, 2022Credit SuisseOutperformInitialise
Jun 19, 2022Bank of America SecuritiesBuyBuyHold
Apr 26, 2022CitigroupBuyUpgrade
Apr 25, 2022JefferiesHoldDowngrade

Charles River Laboratories's last stock rating was published by CLSA on Oct 23, 2024. The company Initialise its CRL rating from "null" to "Underperform".

Charles River Laboratories Financial Forecast

Charles River Laboratories Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue-----------------$1.03B$1.06B$1.03B$1.10B$989.16M$973.13M$913.93M$905.05M$895.94M$914.61M$824.57M$790.99M$743.30M
Avg Forecast$1.22B$1.16B$1.09B$1.09B$1.11B$1.08B$1.06B$1.05B$1.04B$1.03B$1.01B$988.02M$985.70M$975.99M$1.02B$992.31M$991.25M$1.00B$1.05B$986.31M$1.04B$970.43M$995.18M$910.10M$888.27M$906.90M$880.72M$798.20M$756.86M$716.88M
High Forecast$1.24B$1.18B$1.11B$1.11B$1.13B$1.10B$1.07B$1.07B$1.06B$1.04B$1.02B$996.83M$999.02M$979.93M$1.02B$992.31M$999.99M$1.03B$1.07B$1.00B$1.05B$970.43M$995.18M$910.10M$888.27M$906.90M$880.72M$798.20M$756.86M$716.88M
Low Forecast$1.20B$1.14B$1.07B$1.07B$1.09B$1.06B$1.04B$1.03B$1.03B$1.01B$988.22M$974.16M$973.71M$972.05M$1.02B$992.31M$982.33M$990.09M$1.03B$967.50M$1.02B$970.43M$995.18M$910.10M$888.27M$906.90M$880.72M$798.20M$756.86M$716.88M
# Analysts4563333323479855612775555666688
Surprise %-----------------1.03%1.01%1.04%1.06%1.02%0.98%1.00%1.02%0.99%1.04%1.03%1.05%1.04%

Charles River Laboratories's average Quarter revenue forecast for Dec 23 based on 6 analysts is $991.25M, with a low forecast of $982.33M, and a high forecast of $999.99M. CRL's average Quarter revenue forecast represents a -3.45% decrease compared to the company's last Quarter revenue of $1.03B (Sep 23).

Charles River Laboratories EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4563333323479855612775555666688
EBITDA-----------------$225.49M$164.94M$242.49M$315.13M$209.09M$185.42M$195.58M$205.38M$208.41M$176.66M$157.53M$233.58M$213.72M
Avg Forecast$300.89M$286.17M$268.22M$269.85M$273.40M$267.28M$260.37M$258.72M$257.76M$252.97M$248.50M$243.71M$243.14M$240.75M$252.67M$231.40M$244.51M$246.79M$259.92M$210.37M$256.56M$234.31M$240.29M$191.24M$214.48M$218.97M$212.65M$131.04M$182.75M$173.09M
High Forecast$306.06M$291.09M$272.83M$274.49M$278.10M$271.87M$264.85M$263.17M$262.19M$257.32M$252.77M$245.89M$246.43M$241.72M$252.67M$277.68M$246.67M$254.07M$264.39M$252.44M$307.87M$234.31M$240.29M$229.49M$214.48M$218.97M$212.65M$157.25M$182.75M$173.09M
Low Forecast$295.15M$280.71M$263.11M$264.71M$268.19M$262.18M$255.41M$253.79M$252.84M$248.15M$243.76M$240.30M$240.19M$239.77M$252.67M$185.12M$242.31M$244.23M$254.96M$168.29M$205.24M$234.31M$240.29M$152.99M$214.48M$218.97M$212.65M$104.83M$182.75M$173.09M
Surprise %-----------------0.91%0.63%1.15%1.23%0.89%0.77%1.02%0.96%0.95%0.83%1.20%1.28%1.23%

6 analysts predict CRL's average Quarter EBITDA for Dec 23 to be $244.51M, with a high of $246.67M and a low of $242.31M. This is 8.44% upper than Charles River Laboratories's previous annual EBITDA (Sep 23) of $225.49M.

Charles River Laboratories Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4563333323479855612775555666688
Net Income-----------------$87.39M$97.02M$103.13M$187.41M$96.47M$109.32M$93.02M$139.83M$103.43M$88.45M$61.53M$143.19M$102.91M
Avg Forecast$185.17M$165.72M$136.45M$138.72M$159.39M$150.27M$143.97M$133.82M$146.00M$136.44M$129.81M$122.29M$131.23M$124.97M$123.50M$111.32M$123.90M$121.58M$136.10M$101.20M$146.96M$129.74M$141.97M$92.00M$126.09M$133.98M$123.41M$51.98M$109.32M$93.26M
High Forecast$189.31M$169.42M$139.50M$141.82M$162.95M$153.63M$147.19M$136.81M$149.26M$139.49M$132.71M$133.77M$135.90M$125.01M$123.50M$133.58M$128.56M$128.77M$139.14M$121.43M$176.35M$129.74M$141.97M$110.40M$126.09M$133.98M$123.41M$62.37M$109.32M$93.26M
Low Forecast$180.58M$161.61M$133.07M$135.28M$155.44M$146.54M$140.40M$130.50M$142.38M$133.06M$126.60M$117.30M$127.08M$124.93M$123.49M$89.05M$116.64M$119.53M$132.72M$80.96M$117.57M$129.74M$141.97M$73.60M$126.09M$133.98M$123.41M$41.58M$109.32M$93.26M
Surprise %-----------------0.72%0.71%1.02%1.28%0.74%0.77%1.01%1.11%0.77%0.72%1.18%1.31%1.10%

Charles River Laboratories's average Quarter net income forecast for Dec 23 is $123.90M, with a range of $116.64M to $128.56M. CRL's average Quarter net income forecast represents a 41.78% increase compared to the company's last Quarter net income of $87.39M (Sep 23).

Charles River Laboratories SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4563333323479855612775555666688
SG&A-----------------$176.11M$199.76M$174.85M$199.64M$183.71M$131.71M$150.03M$144.11M$148.57M$171.50M$155.73M$143.03M$128.29M
Avg Forecast$220.02M$209.26M$196.13M$197.32M$199.92M$195.44M$190.39M$189.19M$188.48M$184.98M$181.71M$178.21M$177.79M$176.04M$184.76M$179.54M$178.79M$180.46M$190.06M$163.22M$153.94M$175.04M$179.50M$148.38M$160.22M$163.58M$158.86M$131.56M$136.52M$129.30M
High Forecast$223.80M$212.86M$199.50M$200.72M$203.36M$198.80M$193.67M$192.44M$191.72M$188.16M$184.84M$179.80M$180.20M$176.75M$184.76M$215.45M$180.37M$185.78M$193.33M$195.86M$184.73M$175.04M$179.50M$178.05M$160.22M$163.58M$158.86M$157.87M$136.52M$129.30M
Low Forecast$215.82M$205.27M$192.39M$193.56M$196.11M$191.72M$186.76M$185.58M$184.89M$181.46M$178.25M$175.71M$175.63M$175.33M$184.76M$143.63M$177.19M$178.59M$186.44M$130.57M$123.15M$175.04M$179.50M$118.70M$160.22M$163.58M$158.86M$105.24M$136.52M$129.30M
Surprise %-----------------0.98%1.05%1.07%1.30%1.05%0.73%1.01%0.90%0.91%1.08%1.18%1.05%0.99%

Charles River Laboratories's average Quarter SG&A projection for Dec 23 is $178.79M, based on 6 Wall Street analysts, with a range of $177.19M to $180.37M. The forecast indicates a 1.52% rise compared to CRL last annual SG&A of $176.11M (Sep 23).

Charles River Laboratories EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4563333323479855612775555666688
EPS-----------------$1.70$1.89$2.02$3.68$1.90$2.15$1.84$2.77$2.05$1.76$1.23$2.88$2.07
Avg Forecast$3.59$3.21$2.65$2.69$3.09$2.91$2.79$2.59$2.83$2.65$2.52$2.37$2.54$2.42$2.39$2.06$2.40$2.36$2.64$2.59$2.75$2.50$2.74$2.72$2.43$2.58$2.38$2.19$2.11$1.80
High Forecast$3.67$3.28$2.70$2.75$3.16$2.98$2.85$2.65$2.89$2.70$2.57$2.59$2.63$2.42$2.39$2.06$2.49$2.50$2.70$2.65$2.81$2.50$2.74$2.72$2.43$2.58$2.38$2.19$2.11$1.80
Low Forecast$3.50$3.13$2.58$2.62$3.01$2.84$2.72$2.53$2.76$2.58$2.45$2.27$2.46$2.42$2.39$2.06$2.26$2.32$2.57$2.52$2.68$2.50$2.74$2.72$2.43$2.58$2.38$2.19$2.11$1.80
Surprise %-----------------0.72%0.72%0.78%1.34%0.76%0.79%0.68%1.14%0.79%0.74%0.56%1.37%1.15%

According to 6 Wall Street analysts, Charles River Laboratories's projected average Quarter EPS for Dec 23 is $2.40, with a low estimate of $2.26 and a high estimate of $2.49. This represents a 41.29% increase compared to CRL previous annual EPS of $1.70 (Sep 23).

Charles River Laboratories Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CDNACareDx$22.14$37.5069.38%Buy
ICLRICON Public Limited Company$203.26$337.0065.80%Buy
IQVIQVIA$196.64$252.8028.56%Buy
IDXXIDEXX Laboratories$427.09$510.0019.41%Buy
GHGuardant Health$34.84$40.6016.53%Buy
MTDMettler-Toledo$1.25K$1.41K13.28%Hold
LHLaboratory Corporation of America$230.95$258.2011.80%Buy
RVTYRevvity$114.75$127.8611.42%Buy
CRLCharles River Laboratories$189.33$209.0010.39%Buy
AAgilent$136.46$147.408.02%Buy
MEDPMedpace$348.48$369.676.08%Hold
ILMNIllumina$143.12$147.783.26%Buy
WATWaters$373.72$356.80-4.53%Buy

CRL Forecast FAQ

Is Charles River Laboratories a good buy?

Yes, according to 11 Wall Street analysts, Charles River Laboratories (CRL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 54.55% of CRL's total ratings.

What is CRL's price target?

Charles River Laboratories (CRL) average price target is $209 with a range of $151 to $240, implying a 14.74% from its last price of $182.15. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Charles River Laboratories stock go up soon?

According to Wall Street analysts' prediction for CRL stock, the company can go up by 14.74% (from the last price of $182.15 to the average price target of $209), up by 31.76% based on the highest stock price target, and down by -17.10% based on the lowest stock price target.

Can Charles River Laboratories stock reach $300?

CRL's average twelve months analyst stock price target of $209 does not support the claim that Charles River Laboratories can reach $300 in the near future.

What are Charles River Laboratories's analysts' financial forecasts?

Charles River Laboratories's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4.3B (high $4.37B, low $4.21B), average EBITDA is $1.06B (high $1.08B, low $1.04B), average net income is $587.45M (high $600.58M, low $572.89M), average SG&A $774.94M (high $788.27M, low $760.17M), and average EPS is $11.39 (high $11.64, low $11.11). CRL's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $4.56B (high $4.64B, low $4.47B), average EBITDA is $1.13B (high $1.14B, low $1.1B), average net income is $626.07M (high $640.06M, low $610.55M), average SG&A $822.73M (high $836.88M, low $807.04M), and average EPS is $12.14 (high $12.41, low $11.84).

Did the CRL's actual financial results beat the analysts' financial forecasts?

Based on Charles River Laboratories's last annual report (Dec 2023), the company's revenue was $4.13B, beating the average analysts forecast of $4.03B by 2.42%. Apple's EBITDA was $617.26M, missing the average prediction of $961.59M by -35.81%. The company's net income was $480.37M, missing the average estimation of $482.77M by -0.50%. Apple's SG&A was $747.86M, beating the average forecast of $712.53M by 4.96%. Lastly, the company's EPS was $9.38, missing the average prediction of $9.99 by -6.07%. In terms of the last quarterly report (Sep 2023), Charles River Laboratories's revenue was $1.03B, beating the average analysts' forecast of $1B by 2.61%. The company's EBITDA was $225.48M, missing the average prediction of $246.79M by -8.63%. Charles River Laboratories's net income was $87.39M, missing the average estimation of $121.58M by -28.13%. The company's SG&A was $176.11M, missing the average forecast of $180.46M by -2.41%. Lastly, the company's EPS was $1.7, missing the average prediction of $2.36 by -27.88%